Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Synlogic	Lipocine	Galectin Therapeutics	Liminal BioSciences	Hepion Pharmaceuticals
Symbol	NASDAQ:SYBX	NASDAQ:LPCN	NASDAQ:GALT	NASDAQ:LMNL	NASDAQ:HEPA
Price Information
Current Price	$3.14	$1.39	$4.00	$4.79	$1.60
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.6	1.4	1.4	1.1	1.1
Analysis Score	3.4	3.5	3.5	3.1	0.0
Community Score	2.7	2.8	2.7	1.8	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	0.8	0.0	1.7
Earnings & Valuation Score	1.3	0.6	0.0	0.6	1.3
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$13.25	$3.00	$14.00	$18.00	$80.00
% Upside from Price Target	321.97% upside	115.83% upside	250.00% upside	275.78% upside	4,900.00% upside
Trade Information
Market Cap	$128.27 million	$122.72 million	$228.62 million	$143.43 million	$121.96 million
Beta	2.2	0.75	2.04	1.87	1.47
Average Volume	908,940	3,943,150	1,933,236	728,801	4,965,481
Sales & Book Value
Annual Revenue	$2.22 million	$170,000.00	N/A	$3.70 million	N/A
Price / Sales	57.78	721.91	N/A	38.77	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.86 per share	$0.25 per share	$0.76 per share	$3.06 per share	$4.19 per share
Price / Book	0.65	5.56	N/A	1.57	N/A
Profitability
Net Income	$-51,370,000.00	$-13,010,000.00	$-13,290,000.00	$-155,020,000.00	$-6,720,000.00
EPS	($1.70)	($0.50)	($0.39)	($10.94)	($5.95)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-2,761.83%	N/A	N/A	-2,758.32%	N/A
Return on Equity (ROE)	-41.64%	-195.34%	-56.13%	-196.39%	-116.73%
Return on Assets (ROA)	-34.39%	-88.86%	-49.42%	-88.62%	-78.47%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.22%	N/A	2.42%	0.02%
Current Ratio	16.42%	4.27%	13.62%	2.17%	3.63%
Quick Ratio	16.42%	4.27%	13.62%	1.75%	3.63%
Ownership Information
Institutional Ownership Percentage	39.53%	10.87%	17.58%	13.45%	2.97%
Insider Ownership Percentage	17.95%	10.50%	40.70%	N/A	0.10%
Miscellaneous
Employees	72	11	6	251	13
Shares Outstanding	40.85 million	88.29 million	57.16 million	29.94 million	76.23 million
Next Earnings Date	5/13/2021 (Confirmed)	8/5/2021 (Estimated)	5/10/2021 (Estimated)	5/12/2021 (Estimated)	7/5/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	-$0.20 Earnings Per Share Expected for Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) This Quarter americanbankingnews.com - May 7 at 1:36 AM
	Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ apnews.com - May 6 at 8:20 AM
	Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH finance.yahoo.com - May 6 at 8:20 AM
	Weak fundamental momentum pushes Hepion Pharmaceuticals Inc. (HEPA) lower marketingsentinel.com - May 5 at 12:17 PM
	Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Decline in Short Interest americanbankingnews.com - May 2 at 6:42 AM
	Hepion Pharmaceuticals Presents Machine Learning "Learn and Confirm" Modeling Strategy at 4th Global NASH Congress benzinga.com - May 1 at 9:19 AM
	Hepion Pharmaceuticals Inc (HEPA) investing.com - April 30 at 2:01 PM
	After A 5.95% Rise In The Last Week, Does Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Still Make Sense To Buy? marketingsentinel.com - April 30 at 1:21 PM
	Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th ... apnews.com - April 29 at 10:14 AM
	Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress finance.yahoo.com - April 29 at 10:14 AM
	Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA): A Disaster In The Making Or A Gold Mine? marketingsentinel.com - April 27 at 2:45 PM
	Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Jumps 2.98% in Recent Session, Here’s Everything You Need To Know stocksregister.com - April 26 at 8:24 AM
	Here’s Why Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is an Attractive Pick for Investors Now stocksregister.com - April 21 at 12:31 PM
	Analysts Expect Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Will Post Earnings of -$0.20 Per Share americanbankingnews.com - April 19 at 6:36 PM
	Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expected to Announce Earnings of -$0.20 Per Share americanbankingnews.com - April 19 at 6:36 PM
	Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Rises By 57.6% americanbankingnews.com - April 17 at 3:06 AM
	Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Share Price Tumble Recently, But Trouble May Still Be Afoot stocksregister.com - April 13 at 10:18 AM
	Small Cap Stock Hepion Pharmaceuticals, Inc. (HEPA) is a Buy – Analysts marketingsentinel.com - April 12 at 1:07 PM
	Nobel Laureate Dr. Michael Houghton joins API Scientific Advisory Board markets.businessinsider.com - March 30 at 7:09 PM
	Market Analysts see Hepion Pharmaceuticals Inc. [HEPA] gaining to $14. Time to buy? dbtnews.com - March 29 at 1:01 PM
	ENDRA Life Sciences Inc.: ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update finanznachrichten.de - March 25 at 6:47 PM
	Brookline Capital Markets Sticks to Their Buy Rating for Hepion Pharmaceuticals (HEPA) smarteranalyst.com - March 23 at 8:44 PM
	Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies benzinga.com - March 23 at 1:42 PM
	DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic ... apnews.com - March 23 at 8:01 AM
	DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431 benzinga.com - March 23 at 8:01 AM

Date	Company	Brokerage	Action
3/25/2021	Synlogic	SVB Leerink	Boost Price Target
3/24/2021	Synlogic	Jonestrading	Initiated Coverage
1/13/2021	Synlogic	Chardan Capital	Boost Price Target
8/10/2020	Synlogic	HC Wainwright	Reiterated Rating
5/10/2020	Synlogic	Oppenheimer	Reiterated Rating
11/13/2019	Synlogic	Piper Jaffray Companies	Reiterated Rating
8/21/2019	Synlogic	Citigroup	Downgrade
8/9/2019	Synlogic	Wedbush	Reiterated Rating
12/10/2020	Lipocine	LADENBURG THALM/SH SH	Upgrade
8/10/2018	Lipocine	Canaccord Genuity	Reiterated Rating
4/3/2020	Galectin Therapeutics	B. Riley	Reiterated Rating
3/26/2021	Liminal BioSciences	Leede Jones Gab	Reiterated Rating
1/29/2021	Liminal BioSciences	Bloom Burton	Downgrade
12/21/2020	Liminal BioSciences	Piper Sandler	Initiated Coverage
8/11/2020	Liminal BioSciences	Echelon Wealth Partners	Reiterated Rating
12/1/2020	Hepion Pharmaceuticals	Roth Capital	Boost Price Target

(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources